At the end of August,MedtronicRelease the latest quarterly financial report (as of July 28):

• Global revenue of $7.7 billion, a year-on-year increase of 4.5%;

• Its cardiovascular businessYear-on-year +5.5%, accounting for 37%, is its largest business segment, with some products experiencing growth of up to double digits.

  
  

Medtronic invented the world's first battery-powered portable external pacemaker, and has experienced more than 70 years of innovation and ups and downs.In terms of business revenue, it has firmly held the top position among global medical device companies for nearly a decade. It is also a "top player" in the field of cardiac and vascular devices, with many of its cardiac and vascular products representing the highest standards in the industry.。

The CIIE is precisely the crucial platform for such products to enter the Chinese market.

As of the end of September, the opening of the 6th CIIE is imminent,What cutting-edge cardiovascular products will Medtronic bring this time? And what spillover results have emerged from the star exhibits of previous sessions?Around the CIIE, both inside and outside, let's make an integrated review.

This year marks the sixth consecutive year that Medtronic has participated in the CIIE, continuing with the theme "Transforming Life with Technology," showcasing over 60 exhibits, including six groundbreaking new products making their "global debut and China debut."Among them, five are innovative products from the field of cardiology and vascular-related areas.`, which fully demonstrates its emphasis and strength in this field.`

Atrial fibrillation is the most common type of arrhythmia in clinical practice, with a large patient population. It is also an important factor leading to heart failure and even sudden cardiac death. Apart from medication, minimally invasive catheter ablation is currently the best approach for treating atrial fibrillation.

Following the two major technological approaches of heat (radiofrequency ablation) and cold (cryoablation), Medtronic has once again brought the world's first exhibition this year.PulseSelect™ Pulsed Field Ablation System——Bipolar and biphasic high-voltage electrical pulses induce apoptosis in ectopic myocardial cells while avoiding unnecessary damage to surrounding tissues, which is considered the latest ablation technology in the field of electrophysiology, balancing safety and efficacy.

The results of the first IDE study applying PFA technology, released in March this year, showed that the application of PulseSelect™The incidence of adverse events in atrial fibrillation ablationOnly 0.7%, which can effectively isolate the pulmonary veins and treat paroxysmal or persistent atrial fibrillation. This product is also the first cardiac pulsed field ablation product to enter the NMPA green approval channel.

Medtronic at CIIE

PulseSelect™ Pulsed Field Ablation System

It is worth noting that,Medtronic Is Expected to Become the First Provider in the Electrophysiology Industry to Offer a Full Range of "Cryo, Heat, and Electrical" Electrophysiology Solutions。In addition to PulseSelect™,DiamondTemp™Radiofrequency Ablation SystemAnd with Medtronic global cryotherapyMember of the Balloon Family with Millions of Clinical Practices in FranceArctic Front Advance Pro™ Balloon Cryoablation CatheterWill also make an appearance at this year's CIIE.

As its flagship product, Medtronic has consistently led the industry in technological iterations of cardiac pacemakers. At the 2018 CIIE, Medtronic introduced the "world's smallest pacemaker," the Micra VR (single-chamber), which was approved for marketing in 2019. In May 2022, the next-generation Micra AV (dual-chamber) also received approval from the NMPA and officially launched in China.

It is reported that since its launch in 2019, the Micra series of products have cumulatively completed in China.Approximately 10,000 surgeries。

• First, by reducing chip power consumption and improving battery performance, it has enhanced40%Service life, can work non-stop in the human body for up to nearly 17 years;

• Second, it is equipped with a smarter algorithm and achieves higher implant safety at the same time.

  
  

▲Medtronic Micra™ VR 2, Micra™ AV 2

It is reported that the extension of battery life means that thereMore than 80%Patients using the Micra leadless pacemaker need only one device in their lifetime, reducing the need for pacemaker replacement and thereby lowering the overall treatment burden for bradycardia patients.

In addition, the first exhibits in China also include two thoracoabdominal aortic aneurysm products: the Heli-FX™ EndoAnchor™ system, designed for fixation and sealing between endovascular aortic stent grafts and native arteries, the Concerto detachable coil for peripheral arterial and venous embolization, and the SimuForm™ semi-rigid shaping ring for cardiac surgical valve repair.

Among these,Heli-FX™ EndoAnchor™ System, when combined with the Endurant stent graft system from Medtronic, forms the ESAR procedure, becomingThe First in the WorldThe short-necked infrarenal abdominal aortic aneurysm (AAA) solution approved by the FDA significantly reduces the risk of complications such as endoleaks during the surgical treatment of this aortic aneurysm disease.SimuForm™ Semi-Rigid Ring, adopting a dynamic design, presents a saddle shape during cardiac systole and an O-shape during diastole after implantation, maximizing conformity to the physiological characteristics of mitral valve motion.Significantly Improve the Treatment Outcomes of Valve RepairThese two innovations are both derived from Medtronic's precise grasp of the clinical needs of various heart surgeries, and are closely related to its 70 years of accumulation and breakthroughs in the cardiac field.

Hypertension often requires lifelong medication, but many patients experience loss of control over their condition due to issues such as poor drug efficacy and the inability to adhere to treatment over the long term, highlighting an urgent need for new therapeutic approaches.Renal Artery Sympathetic Denervation (RDN)As a comprehensive and revolutionary method for lowering blood pressure, this minimally invasive surgery involves inserting a radiofrequency ablation catheter into the renal arteries. By using radiofrequency energy within a safe range, it disrupts part of the renal sympathetic nerves, reducing excessive sympathetic nerve activity, thereby achieving long-term stable blood pressure control in a single procedure.

Since 2009, when the minimally invasive interventional innovation therapy RDN was first reported, Medtronic has never ceased its exploration and breakthroughs in this technology. It has successively released relevant clinical research data worldwide, verifying the safety, reliability, and long-lasting blood pressure-lowering effects of this technology.

In 2020, MedtronicSymplicity Spyral™ Renal Artery Sympathetic Multipoles Radiofrequency Ablation SystemAnd the catheter has received the U.S. FDA Breakthrough Device Designation, and has been clinically applied in more than 60 countries and regions worldwide, benefiting over 20,000 people globally. It will make another appearance at this year’s CIIE.

Medtronic at CIIE

Symplicity Spyral™

Renal Artery Sympathetic Multi-Polar Radiofrequency Ablation System and Catheter

ItsHis highly anticipated exhibits also include those used in Medtronic's areas of expertise, such as aortic interventions.Valiant Captivia Thoracic Stent Graft SystemAndEndurant Abdominal Aortic Stent Graft System, and acts as an "artificial lung" in ECMO therapyNautilus Smart ECMO Oxygenatoretc.

At this year's CIIE, several star exhibits from Medtronic will once again appear, showcasing their "overflow results."

①"The Evolution of the 'Father of Self-Expanding Heart Valves' Has Covered 25 Provinces Across China"

Medtronic's TAVR is hailed as the "pioneer of self-expanding heart valves."CoreValve Evolut PRO Transcatheter Aortic Valve SystemIt is the third-generation innovative TAVR product from Medtronic, used for treating severe aortic valve stenosis. Compared with traditional surgical procedures, TAVR is a vascular interventional surgery that boasts numerous advantages such as minimal trauma and quick recovery, and is acclaimed as the "heart-protecting procedure without opening the chest."

▲Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve System

It is reported that Evolut PRO made its debut at the CIIE in 2021, gained NMPA approval for marketing in China in December of the same year, and was officially put into clinical use in March 2022.As of now, surgeries have been carried out in over 90 centers across 25 provinces in China.

Evolut PRO is the first TAVR product launched by Medtronic in China. In April this year, its expanded indications were approved again, making it the first TAVR valve in China that can be used for surgical patients with medium to low risk.

② Remote monitoring of heart rhythms has benefited more than 3,000 cardiac patients.

After the pacemaker implantation surgery, regular follow-ups and device adjustments are required. However, due to financial constraints, distance, mobility issues, and other reasons, many patients fail to attend follow-up examinations on time, leading to a phenomenon of "valuing surgery but neglecting follow-ups."

At this CIIE, Medtronic has brought two cardiac rhythm management products that can remotely monitor heart rate data, helping doctors manage diseases, reduce hospitalization rates and mortality, while significantly easing the postoperative burden on patients.

One isMyCareLink Cardiac Implantable Electronic Device Data Transmitter, the product transmits follow-up data via China Mobile's cellular network to a secure server located in China, allowing clinicians to view it on the CareLink website. It is currently the only remote follow-up system for cardiac implantable electronic devices (CIED) with a local server in China.

It is reported that after the product's debut at the 2019 CIIE, Medtronic collaborated with Tongren Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, to launch the "Remote Community Follow-up Project for Patients with Implanted Cardiac Electronic Devices." To date, all 10 subdistricts and towns in Changning District have achieved full coverage of remote follow-ups, benefiting...More than 3,000Patients with heart disease have become one of the typical cases of the "spillover effect" of Medtronic's cardiovascular products at the CIIE.

Medtronic at CIIE

MyCareLink

Cardiac Implantable Electronic Device Data Transmitter

AnotherThe payment isPercepta™ CRTP MRI SureScan™ Implantable Cardiac Resynchronization Therapy Pacemaker, this product is a long-life intelligent device and also the first CRT-P with Bluetooth communication function approved by NMPA. In the future, it will be able to communicate with mobile phones/programmers, facilitating disease management for doctors and patients.

Medtronic at CIIE

Percepta™ CRTP MRI SureScan™

Implantable Cardiac Resynchronization Therapy Pacemaker

The cardiovascular intervention field has extremely high technical barriers and strict regulation, with a highly concentrated global market, and Medtronic is undoubtedly one of the top leaders among leading companies.

• In 1958, it launched the world's first implantable cardiac pacemaker;

• In 2011, the first pacemaker for MRI was launched.

• In 2015, the first leadless pacemaker was launched...

  
  

In 1989, Medtronic entered China and has been developing in the country for over 30 years. Today, China has become the largest single market for Medtronic globally, outside of the United States. Encouragingly, as a top global innovator in medical devices, Medtronic is not only focused on the high-end market but is also making every effort to promote the availability of quality medical resources at the grassroots level.

In terms of accelerating the implementation of innovative products，Capitalizing on a series of policy advantages such as the "New National Nine Articles" and the "Greater Bay Area Medical Device Access Program," Medtronic has successfully performed the first-in-China implant surgeries for a range of innovative cardiovascular devices.

• In September 2020, the Micra AV leadless dual-chamber pacemaker was successfully applied clinically for the first time in China at the Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone.

• In April this year, Boao Super Hospital successfully completed the clinical application of RDN using the Symplicity Spyral™ catheter system for the first time in China.

  
  

▲ In March this year, at the "2023 International Innovative Pharmaceutical and Medical Device Enterprise Exchange Conference" hosted by the Administration of Boao Lecheng International Medical Tourism Pilot Zone in Hainan and co-organized by West China Medical College of Sichuan University, Medtronic was awarded the "2022 Best Specialty Disease Cooperation Award" in recognition of its outstanding contributions in the strategic cooperation with the Administration of Boao Pilot Zone.

Local Production Aspect，Medtronic is one of the few multinational companies that has invested in and set up cardiovascular-related production lines in China.

• In June 2023, Medtronic officially launched the construction of its first production line in Lingang New Area, Shanghai, aiming to further meet the rapidly growing needs of Chinese patients with heart disease and thereby promote the high-quality development of China's high-end medical device industry.

In terms of training empowerment，To support the growth and development of medical professionals, Medtronic has continuously invested funds and resources over the years to promote broader professional clinical education.

• At the Medtronic Innovation Centers in Shanghai and Chengdu, Medtronic offers professional clinical simulation training courses such as transcatheter aortic valve replacement and leadless pacemaker implantation. China is also the only market in the world where Medtronic has two innovation centers.Each year, Medtronic trains an average of approximately 4,500 cardiologists in China.

• Actively promote the下沉 of heart-related surgical procedures. For example, starting from March 2020, Medtronic actively participated in the practice of medical assistance between Shanghai and Yunnan, helping to build a benchmark hospital for pacemaker therapy in a county in Yunnan, enhancing the cardiovascular disease treatment capabilities of grassroots hospitals, and contributing to the goal of "major illnesses not leaving the county."

  
  

▲Doctor Training in Progress at the Medtronic Innovation Center

• According to statistics, each year in China, more than 50,000 patients receive post-operative management services for Medtronic cardiac implantable electronic devices, and the number of users of the Medtronic Heart Rhythm Manager WeChat Official Account has also exceeded 50,000 this year, providing a more convenient digital connection between doctors and arrhythmia patients.

  
  

In terms of industry cooperation，The diagnosis and treatment chain of heart disease is long. Medtronic also actively collaborates with vertical and horizontal industry partners to expand disease education from patient groups to the healthy public.

• At the 2022 CIIE, Medtronic signed an agreement with Omron to explore an innovative cooperation model for early screening in the fields of arrhythmia and atrial fibrillation by integrating therapy training capabilities and disease screening capabilities.

• In March 2023, a strategic cooperation agreement was signed with ZOLL, a defibrillator giant, to increase the popularity of defibrillation treatment devices both inside and outside hospitals by integrating professional training and technical service capabilities. This collaboration aims to enhance public awareness of first aid in the field of sudden cardiac arrest and reasonably advance the primary and secondary prevention of cardiac arrest.

  
  

All of these comprehensive business model innovations either directly take place on the stage of the CIIE or, thanks to the immense influence of the CIIE, accelerate their establishment and implementation in China. This demonstrates that...Medtronic is playing a "leading role" in the cardiac and vascular fields, continuously taking on a guiding role in its deepening layout in China. Leveraging the momentum of the CIIE, it has further accelerated its transformation from an exhibitor to an investor and then to an ecosystem creator.

Someone once described that if all human knowledge were encompassed in a circle, a Ph.D. would be equivalent to reaching the edge, and with a bit more effort, one could open up new frontiers in the human knowledge system.

The significance of Medtronic's innovative products in China is similar — driving the healthcare system to new boundaries, and even a small technological breakthrough could mean "a lifeline" for millions of patients in this populous country.

· END ·

Centralized Procurement, Anti-Corruption, Corporate Adjustments… Where Should Marketing Professionals Go Amidst the Changes in China’s Medical Industry?

--Featured Recommendations--

       

Pharmaceuticals | Biological Medicine | ADC | mRNA | CAR—T | PD-1 | Medical Device | Imaging | IVD | Cardiovascular | Orthopedics | Oral Cavity | Ophthalmology | Surgical Robot | Internet Healthcare| Hospital | CXO | Life ScienceStudy

Deep Original | Annual Review | Trend Analysis | Cross-Cycle Series | Stock Market Dynamics | Enterprise Dynamics | Executive Moves | Pharmaceutical Financial Reports | Medical Device Financial Report | Heavyweight M&A | Strategic Spin-off | Executive Interview | Compensation | Policy Analysis | Medical Insurance Negotiation | DRG/DIP | Centralized Procurement | JPM | Latest News | CIIE | CMEF

Medical Device Rankings | Medtronic | Abbott | Johnson & Johnson Medical | Siemens Healthineers | BD | Stryker | GE Healthcare | Roche Diagnostics | Philips | Boston Scientific | Mindray Medical | United Imaging Healthcare | Minimally Invasive Medical | Lepu Medical | Weigao | Danaher | Thermo Fisher

Pharmaceutical Rankings | Pfizer | AbbVie | Roche Pharmaceuticals | Johnson & Johnson Pharmaceutical | Merck & Co. |  AstraZeneca | Bristol-Myers Squibb | Sanofi | Novartis | GSK | Hengrui | BeiGene | ShiYao | Innovent Biologics | Junshi Biosciences | Legend Biotech | I-Mab Biopharma | CStone Pharmaceuticals | Rongchang Bio | Zai Lab | WuXi AppTec | Qiming Venture Partners | Eli Lilly Asia 

Creation is not easy, sharing, watching, and liking.

Recharge MedTrend ↓